Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pellucid Marginal Corneal Degeneration: early-phase trial registry
2 of 4 indexed Pellucid Marginal Corneal Degeneration trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Pellucid Marginal Corneal Degeneration: 4 US clinical trials tracked, 2 recruiting.
Pellucid Marginal Corneal Degeneration is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Cornea Associates of Texas, running 1 of these trials.
Enrollment posture brief
Registry condition pellucid-marginal-corneal-degeneration
OPEN 2 | RECR 50% | LATE 1 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Pellucid Marginal Corneal Degeneration lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pellucid Marginal Corneal Degeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pellucid Marginal Corneal Degeneration is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia
Goodman Eye Center
NCT04094090
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
Woolfson Eye Institute
NCT07124910
Wavefront Guided Scleral Lenses for Keratoconus and Irregular Astigmatism
Cornea and Laser Eye Institute
NCT04698590
Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution
Cornea Associates of Texas
NCT04667572
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pellucid Marginal Corneal Degeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pellucid Marginal Corneal Degeneration trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pellucid Marginal Corneal Degeneration page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Pellucid Marginal Corneal Degeneration trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Cornea Associates of Texas sponsors the most Pellucid Marginal Corneal Degeneration trials on record, review their full trial history before evaluating a specific study. See Cornea Associates of Texas's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pellucid Marginal Corneal Degeneration condition card totals 4 registered trials; most-linked intervention PXL-330 Platinum device for crosslinking with Peschke riboflavin solution; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.